These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 38389844)

  • 1. Degraders in epigenetic therapy: PROTACs and beyond.
    Dai XJ; Ji SK; Fu MJ; Liu GZ; Liu HM; Wang SP; Shen L; Wang N; Herdewijn P; Zheng YC; Wang SQ; Chen XB
    Theranostics; 2024; 14(4):1464-1499. PubMed ID: 38389844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Induced degradation of proteins by PROTACs and other strategies: towards promising drugs].
    Reboud-Ravaux M
    Biol Aujourdhui; 2021; 215(1-2):25-43. PubMed ID: 34397373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Powering up targeted protein degradation through active and passive tumour-targeting strategies: Current and future scopes.
    Venkatesan J; Murugan D; Lakshminarayanan K; Smith AR; Vasanthakumari Thirumalaiswamy H; Kandhasamy H; Zender B; Zheng G; Rangasamy L
    Pharmacol Ther; 2024 Nov; 263():108725. PubMed ID: 39322067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PROTACs in Epigenetic Cancer Therapy: Current Status and Future Opportunities.
    Liu X; Wang A; Shi Y; Dai M; Liu M; Cai HB
    Molecules; 2023 Jan; 28(3):. PubMed ID: 36770884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting epigenetic modulators using PROTAC degraders: Current status and future perspective.
    Webb T; Craigon C; Ciulli A
    Bioorg Med Chem Lett; 2022 May; 63():128653. PubMed ID: 35257896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in epigenetic proteolysis targeting chimeras (Epi-PROTACs).
    Tomaselli D; Mautone N; Mai A; Rotili D
    Eur J Med Chem; 2020 Dec; 207():112750. PubMed ID: 32871345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Major Advances in Emerging Degrader Technologies.
    Luo H; Wu L; He Y; Qin C; Tang X
    Front Cell Dev Biol; 2022; 10():921958. PubMed ID: 35813205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Protein induced proximity and targeted degradations by new degraders: concepts, developments, challenges for clinical applications].
    Reboud-Ravaux M
    Biol Aujourdhui; 2024; 218(1-2):41-54. PubMed ID: 39007776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydrophobic tag-based protein degradation: Development, opportunity and challenge.
    He Q; Zhao X; Wu D; Jia S; Liu C; Cheng Z; Huang F; Chen Y; Lu T; Lu S
    Eur J Med Chem; 2023 Nov; 260():115741. PubMed ID: 37607438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in targeted protein degraders as potential therapeutic agents.
    Yang N; Kong B; Zhu Z; Huang F; Zhang L; Lu T; Chen Y; Zhang Y; Jiang Y
    Mol Divers; 2024 Feb; 28(1):309-333. PubMed ID: 36790583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteolysis-targeting drug delivery system (ProDDS): integrating targeted protein degradation concepts into formulation design.
    Chen Y; Liu F; Pal S; Hu Q
    Chem Soc Rev; 2024 Sep; 53(19):9582-9608. PubMed ID: 39171633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small-Molecule Degraders beyond PROTACs-Challenges and Opportunities.
    Kastl JM; Davies G; Godsman E; Holdgate GA
    SLAS Discov; 2021 Apr; 26(4):524-533. PubMed ID: 33632029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expansion of targeted degradation by Gilteritinib-Warheaded PROTACs to ALK fusion proteins.
    Yokoo H; Tsuji G; Inoue T; Naito M; Demizu Y; Ohoka N
    Bioorg Chem; 2024 Apr; 145():107204. PubMed ID: 38377822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies.
    Peng X; Hu Z; Zeng L; Zhang M; Xu C; Lu B; Tao C; Chen W; Hou W; Cheng K; Bi H; Pan W; Chen J
    Acta Pharm Sin B; 2024 Feb; 14(2):533-578. PubMed ID: 38322348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteolysis targeting chimeras (PROTACs) for epigenetics research.
    Vogelmann A; Robaa D; Sippl W; Jung M
    Curr Opin Chem Biol; 2020 Aug; 57():8-16. PubMed ID: 32146413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation.
    Chen Y; Tandon I; Heelan W; Wang Y; Tang W; Hu Q
    Chem Soc Rev; 2022 Jul; 51(13):5330-5350. PubMed ID: 35713468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemically induced degradation of epigenetic targets.
    Kabir M; Yu X; Kaniskan HÜ; Jin J
    Chem Soc Rev; 2023 Jul; 52(13):4313-4342. PubMed ID: 37314393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of IAP-recruiting BCL-X
    Zhang X; He Y; Zhang P; Budamagunta V; Lv D; Thummuri D; Yang Y; Pei J; Yuan Y; Zhou D; Zheng G
    Eur J Med Chem; 2020 Aug; 199():112397. PubMed ID: 32388279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging targeted protein degradation tools for innovative drug discovery: From classical PROTACs to the novel and beyond.
    Zhong Y; Chi F; Wu H; Liu Y; Xie Z; Huang W; Shi W; Qian H
    Eur J Med Chem; 2022 Mar; 231():114142. PubMed ID: 35092900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones.
    Ishida T; Ciulli A
    SLAS Discov; 2021 Apr; 26(4):484-502. PubMed ID: 33143537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.